(Q66408014)

English

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

short name

MRD (English)

0 references

title

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment (Which May Include High Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT)) in Patients With AL Amyloidosis: Feasibility and Prognostic Significance (English)

0 references

0 references

0 references

United States of America

0 references

start time

21 November 2016

0 references

end time

December 2019

0 references

number of participants

30

0 references

minimum age

18 year

0 references

Identifiers

ClinicalTrials.gov ID

NCT02716103

0 references

(Q66408014)

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)